Improving Performance and Preventing Talent Attrition Through Stock Options
First written in FY2017. 21 of 23 entries say "Advanced", first in FY2018-Q2. Latest entry: FY2026.
106 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「Exercised 12,400 Expired 34,400 3,000 Unexercised balance － － 563,000」
Of the Second Series Stock Acquisition Rights, 12,400 shares were exercised and 34,400 shares expired. Of the Sixth Series Stock Acquisition Rights, 3,000 shares expired, leaving an unexercised balance of 563,000 shares. - FY2026-H1AdvancedAnnual report
「1 July 2025– 31 December 2025 12,400 19,969,200 2 3,471 2 3,489 (Note) Increase due to the exercise of stock acquisition rights.」
During the interim consolidated accounting period, 12,400 common shares were issued upon exercise of stock acquisition rights related to stock options and other instruments. - FY2025AdvancedAnnual report
「The increase of 50,000 in the number of common shares outstanding resulted from the exercise of stock acquisition rights.」
In FY2025, 50,000 common shares were added through the exercise of stock acquisition rights, and share capital and capital surplus each increased by ¥11 million. Meanwhile, 566,000 shares under the Sixth Series Stock Acquisition Rights remained unexercised. - FY2024-Q2AdvancedAnnual report
「The increase resulted from the exercise of share acquisition rights.」
During the second quarter, 8,400 common shares were issued upon exercise of stock acquisition rights related to stock options. - FY2024-Q1AdvancedAnnual report
「1 July 2023–30 September 2023 (Note) 320,800 19,890,000 72 3,449 72 3,468」
During the first quarter, 320,800 common shares were added through the exercise of stock acquisition rights, and share capital and capital surplus each increased by ¥72 million. - FY2023AdvancedAnnual report
「(Note) The increase in common shares outstanding was 4,400 shares from the exercise of stock acquisition rights.」
During the fiscal year, 4,400 common shares were added through the exercise of stock acquisition rights. Unexercised balances disclosed were 20,000 shares under the Fifth Series, 593,000 shares under the Sixth Series and 17,300 shares under the Seventh Series. - FY2023-Q1AdvancedAnnual report
「1 July 2022–30 September 2022 (Note) 1,200 19,566,000 0 3,376 0 3,395」
During the first quarter, 1,200 common shares were issued upon exercise of stock acquisition rights related to stock options. - FY2022-Q3AdvancedAnnual report
「1 January 2022– 31 March 2022 (Note) 400 19,559,600 90 3,375,287 90 3,393,783」
During the third quarter, 400 common shares were added through the exercise of stock acquisition rights, and share capital and capital surplus each increased by ¥90 thousand. - FY2022-Q2AdvancedAnnual report
「The increase resulted from the exercise of share acquisition rights.」
During the second quarter, 2,000 common shares were issued upon exercise of stock acquisition rights related to stock options. - FY2022-Q1AdvancedAnnual report
「1 July 2021– 30 September 2021 (Note) 1 1,200 19,557,200 3,374,635 298 3,393,130 298」
From July through September 2021, 1,200 common shares were added through the exercise of stock acquisition rights, and share capital and capital surplus each increased by ¥298 thousand. - FY2021AdvancedAnnual report
「The increase in common shares outstanding was 65,200 shares from the exercise of stock acquisition rights.」
From July 2020 through June 2021, 65,200 common shares were added through the exercise of stock acquisition rights, increasing the cumulative record of stock option exercises. - FY2021-Q3AdvancedAnnual report
「Increase or decrease in total shares outstanding 21,200 (Note) 1. Increase resulting from the exercise of stock acquisition rights.」
From January through March 2021, 21,200 common shares were added through the exercise of stock acquisition rights, and share capital and capital surplus each increased by ¥4.488 million. - FY2021-Q1AdvancedAnnual report
「Change in total number of shares issued 5,200 (Note) 1. Increase due to the exercise of stock acquisition rights.」
During the first quarter, 5,200 common shares were issued upon exercise of stock acquisition rights related to stock options. - FY2020AdvancedAnnual report
「The increase in issued common shares was an increase of 54,400 shares resulting from the exercise of stock acquisition rights.」
For stock options, exercises covering 54,400 shares were confirmed for the full year. Unvested amounts remaining were 657,000 shares under the Sixth Series and 22,300 shares under the Seventh Series. - FY2020-Q3AdvancedAnnual report
「The increase resulted from the exercise of share acquisition rights.」
During the third quarter, 4,000 shares were issued upon exercise of stock acquisition rights, adding to the record of stock option exercises. - FY2020-Q2AdvancedAnnual report
「The increase resulted from the exercise of share acquisition rights.」
During the second quarter, 22,800 shares and 20,400 shares, for a total of 43,200 shares, were issued upon exercise of stock acquisition rights, increasing share capital and capital surplus as well. - FY2019AdvancedAnnual report
「The increase in common shares outstanding consisted of 9,693,400 shares from a stock split and 49,600 shares from the exercise of stock acquisition rights.」
For stock options, the full-year increase of 49,600 common shares from the exercise of stock acquisition rights was confirmed. The grant and vesting conditions for 38,500 shares under the Seventh Series Stock Acquisition Rights were also disclosed. - FY2019-Q3AdvancedAnnual report
「The increase resulted from the exercise of share acquisition rights.」
During the third quarter, 1,600 shares were issued upon exercise of stock acquisition rights, increasing the number of shares outstanding, share capital and capital surplus. - FY2019-Q2AdvancedAnnual report
「Number of stock acquisition rights (rights) ※ 385」
The Seventh Series Stock Acquisition Rights were issued in an amount of 385 rights, covering 38,500 common shares. The exercise period runs from 19 November 2022 through 18 November 2024. - FY2018AdvancedAnnual report
「Class, particulars and number of shares underlying the stock acquisition rights (shares) Common shares Up to 38,500 shares.」
At the annual general meeting of shareholders held on 26 September 2018, the Company approved the offering terms for the Seventh Series Stock Acquisition Rights, covering up to 38,500 common shares. A scheme was added under which the exercise period runs from the day after 4 years have elapsed from the grant resolution through the day on which 6 years have elapsed. - FY2018-Q2AdvancedAnnual report
「The total number of shares deliverable upon exercise of these stock acquisition rights is 416,500 common shares of the Company. If the number of shares underlying these stock acquisition rights is adjusted under 3. (1) below, the total will be the adjusted number of shares per right multiplied by the number of stock acquisition rights.」
The Company resolved to establish a scheme covering 4,165 newly issued paid stock acquisition rights and 416,500 common shares. The exercise condition is the achievement of ordinary profit of more than ¥2.6 billion to more than ¥3.0 billion in any fiscal year from the fiscal year ending June 2021 through the fiscal year ending June 2025, with the exercisable percentage set in stages at 30%, 60% and 100% after achievement. - FY2018-Q1AchievedAnnual report
「Up to 50,000 common shares.」
Stock options, for which an introduction policy had been outlined in the previous report, were granted on 26 October 2017. They are available to directors, employees and directors of subsidiaries, and cover up to 50,000 common shares. - FY2017First statedAnnual report
「The company will issue stock acquisition rights to the company's directors and employees and the directors and employees of its subsidiaries free of charge, without requiring any cash payment, in order to motivate them to improve the Group's performance, strengthen cohesion across the Group, increase corporate value and prevent the loss of talented personnel.」
The company introduced the free grant of stock acquisition rights to directors and employees as a means of motivating them to improve performance, strengthening cohesion, increasing corporate value and preventing the loss of talented personnel. The combined limit for the fourth and fifth grants is 50,000 common shares, and the rights may be exercised after 3 or 5 years have elapsed from the date of the grant resolution.